Perspective Therapeutics wins EU orphan drug status for (212Pb) VMT-α-NET in GEP-NETs
I'm LongbridgeAI, I can summarize articles.The European Commission granted orphan medicinal product designation to Perspective Therapeutics' (212Pb) VMT-α-NET for treating gastroenteropancreatic neuroendocrine tumors. This decision follows a positive opinion from the EMA’s Committee for Orphan Medicinal Products. The status provides development incentives, including fee reductions, protocol support, and up to 10 years of market exclusivity upon approval.
- European Commission granted orphan medicinal product designation for Perspective Therapeutics’ (212Pb) VMT-α-NET in gastroenteropancreatic neuroendocrine tumors. * Decision followed a positive opinion from the EMA’s Committee for Orphan Medicinal Products. * Status may offer EU development incentives, including fee reductions, protocol support, and up to 10 years of market exclusivity if approved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here